IDYA IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
$17.99 +0.22 (1.24%)
As of 12/02/2022 15:59:47 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 05/23/2019
Outstanding shares: 48,113,501
Average volume: 538,483
Market cap: $854,976,913
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BK0VHF6
Valuation (See tab for details)
PE ratio: -15.71
PB ratio: 2.39
PS ratio: 120.86
Return on equity: -19.69%
Net income %: -803.59%